Destiny Pharma : 10 June 2021 – XF-73 data abstract to be presented at 2021 ECCMID

Destiny Pharma plc
('Destiny Pharma' or 'the Company')

Data to be presented from the successful Phase 2b clinical study of XF-73 nasal gel at the prestigious 2021 ECCMID congress

• XF-73 met its primary end point with >99% nasal aureus reduction within 24 hours
• Excellent clinical safety profile for XF-73 dosed in patients scheduled for cardiac surgery
• Infection prevention expert, Professor Julie Mangino MD to present XF-73 data abstract

Brighton, United Kingdom - 10^th June 2021 - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines to prevent life-threatening infections, today announces that an abstract providing analysis and discussion of the late-breaking data arising from the recently completed Phase 2b clinical study of XF-73 nasal gel has been accepted for presentation at Europe's premier antimicrobials congress, the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), to be held 9 - 12 July, 2021.

Presentation Title: Repeated doses of exeporfinium chloride (XF-73) nasal gel over 24 hours significantly reduced the burden of Staphylococcus aureus nasal carriage in at-risk surgical patients: preliminary results from a Phase 2 study. The presentation will update the audience on the following highlights:

• Met primary endpoint: XF-73 reduced the mean nasal burden of S. aureus in patients undergoing open heart surgery by 2.5 log (CFU/ml) in the 24 hours immediately before surgery a highly statistically significant result, (p<0.0001). This equates to a 99.5% reduction in S. aureus bacterial nasal carriage, which is a very effective reduction by accepted clinical measures.
• XF-73 showed 2.1 log, (>99%), greater reduction than placebo in the same patient population and this difference in reduction of nasal burden of S. aureus was highly statistically significant (p<0.0001). The effect was maintained during surgery, considered the period when the risk for infections is the highest.
• These positive results were achieved with just three doses of 0.2% (w/w) XF-73 nasal gel in the 24 hours before incision and the start of surgery.
• There were no XF-73 nasal gel treatment related adverse events.

Presenting Author: Julie Mangino MD, FSHEA, FIDSA, Professor Emeritus, Department of Internal Medicine, Division of Infectious Diseases, The Ohio State University College of Medicine, US

Abstract #: 04905

Session: LB: Late breaking clinical trial data

Session code: S182

ECCMID (https://www.eccmid.org/) is the world's premier Clinical Microbiology & Infectious Diseases event, bringing together experts from many fields to present their latest findings, and developments and share their expertise.

XF-73 is the lead drug candidate from Destiny Pharma's XF platform, initially being developed for the prevention of post-surgical staphylococcal infections, such as methicillin-resistant Staphylococcus aureus (MRSA), which cause significant complications and increased healthcare costs in the hospital setting. XF-73 has been awarded both Qualified Infectious Disease Product (QIDP) and Fast Track status by the US FDA.

If you would like to meet with Destiny Pharma, please email us on [e-mail]

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
[phone]
[e-mail]

Optimum Strategic Communications
Mary Clark/ Shabnam Bashir/ Manel Mateus
[phone]
[e-mail]

finnCap Ltd (Nominated Advisor & Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
[phone]

WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
[phone]

About Destiny Pharma plc

Destiny Pharma is a UK based, clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence, which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections, and has earlier grant funded XF research projects.

For further information on the company, please visit https://www.destinypharma.com